Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTL CVE:GPH NYSE:OGN NASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$2.54-5.2%$5.03$2.51▼$85.80$2.38M0.051.89 million shs90,429 shsGPHGraphite OneC$1.17C$1.19C$0.65▼C$2.57C$243.86M1.323881357,076 shs307,334 shsOGNOrganon & Co.$13.35+0.2%$8.00$5.69▼$13.44$3.51B1.5719.29 million shs6.77 million shsPHARPharming Group$12.98+8.2%$16.28$8.69▼$21.34$916.71M0.0412,870 shs19,530 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences-5.22%-25.07%-60.98%-42.40%-86.30%GPHGraphite One0.00%-2.50%-8.59%-38.42%+50.00%OGNOrganon & Co.0.00%+0.38%+92.99%+62.55%+52.62%PHARPharming Group+8.17%-23.56%-23.56%-19.33%+43.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$2.54-5.2%$5.03$2.51▼$85.80$2.38M0.051.89 million shs90,429 shsGPHGraphite OneC$1.17C$1.19C$0.65▼C$2.57C$243.86M1.323881357,076 shs307,334 shsOGNOrganon & Co.$13.35+0.2%$8.00$5.69▼$13.44$3.51B1.5719.29 million shs6.77 million shsPHARPharming Group$12.98+8.2%$16.28$8.69▼$21.34$916.71M0.0412,870 shs19,530 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences-5.22%-25.07%-60.98%-42.40%-86.30%GPHGraphite One0.00%-2.50%-8.59%-38.42%+50.00%OGNOrganon & Co.0.00%+0.38%+92.99%+62.55%+52.62%PHARPharming Group+8.17%-23.56%-23.56%-19.33%+43.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 1.67Reduce$54.002,025.98% UpsideGPHGraphite One 3.00BuyC$2.85143.59% UpsideOGNOrganon & Co. 1.57Reduce$11.40-14.57% DownsidePHARPharming Group 2.60Moderate Buy$38.33195.33% UpsideCurrent Analyst Ratings BreakdownLatest PHAR, OGN, GPH, and ARTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$12.00 ➝ $14.004/28/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/28/2026OGNOrganon & Co. Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$5.00 ➝ $14.004/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/14/2026OGNOrganon & Co. Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/13/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/10/2026PHARPharming Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/10/2026PHARPharming Group Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$37.003/30/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)3/27/2026ARTLArtelo Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/24/2026PHARPharming Group HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$37.00(Data available from 5/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A($1.89) per shareN/AGPHGraphite OneN/AN/AC$0.01 per share94.17C$0.61 per shareN/AOGNOrganon & Co.$6.22B0.56$5.78 per share2.31$3.44 per share3.88PHARPharming Group$376.13M2.44$0.20 per share64.72$3.95 per share3.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$12.88M-$62.76N/AN/AN/AN/A-3,401.09%-345.03%5/19/2026 (Estimated)GPHGraphite One-C$4.90M-C$0.06N/AN/AN/AN/A-14.38%-6.61%N/AOGNOrganon & Co.$187M$0.9314.353.881.243.99%99.95%6.22%N/APHARPharming Group$2.85M$0.1681.1329.50N/A3.30%4.68%2.57%N/ALatest PHAR, OGN, GPH, and ARTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2026Q1 2026ARTLArtelo Biosciences-$0.78N/AN/AN/AN/AN/A5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million4/30/2026Q1 2026OGNOrganon & Co.$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 million2/12/2026Q4 2025OGNOrganon & Co.$0.73$0.63-$0.10-$0.79$1.52 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.60%N/A8.60%N/APHARPharming GroupN/AN/AN/AN/AN/ALatest PHAR, OGN, GPH, and ARTL DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026OGNOrganon & Co.quarterly$0.020.6%5/11/20265/11/20266/11/20262/12/2026OGNOrganon & Co.quarterly$0.021.01%2/23/20262/23/20263/12/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A0.170.17GPHGraphite One0.222.420.33OGNOrganon & Co.9.471.971.23PHARPharming Group0.332.592.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%GPHGraphite One0.12%OGNOrganon & Co.77.43%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences11.50%GPHGraphite One28.81%OGNOrganon & Co.1.62%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences5940,000830,000Not OptionableGPHGraphite One20208.43 millionN/ANot OptionableOGNOrganon & Co.10,000262.60 million258.35 millionNot OptionablePHARPharming Group28070.63 million69.16 millionNot OptionablePHAR, OGN, GPH, and ARTL HeadlinesRecent News About These CompaniesPharming Group (PHAR) Gets a Buy from Canaccord GenuityMay 9 at 5:22 PM | theglobeandmail.comPharming Group (NASDAQ:PHAR) Lowered to Hold Rating by Wall Street ZenMay 9 at 2:41 AM | marketbeat.comPharming Group Q1 Earnings Call HighlightsMay 8 at 3:11 PM | marketbeat.comPharming Group (NASDAQ:PHAR) Issues Quarterly Earnings ResultsMay 7 at 6:30 PM | marketbeat.comPharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026May 7 at 3:02 PM | markets.businessinsider.comPharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersMay 7 at 3:02 PM | markets.businessinsider.comPharming Group N.V. (PHAR) Q1 2026 Earnings Call TranscriptMay 7 at 1:03 PM | seekingalpha.comPharming Group (NASDAQ:PHAR) Shares Gap Down After Earnings MissMay 7 at 10:19 AM | marketbeat.comPharming Group N.V. 2026 Q1 - Results - Earnings Call PresentationMay 7 at 7:43 AM | seekingalpha.comPharming earnings in focus: Can rare disease growth offset Q1 dip?May 6, 2026 | investing.comPharming Group (XAMS:PHARM) Q1 2026: Everything You Need To Know Ahead Of EarningsMay 6, 2026 | finance.yahoo.comPharming Group (PHAR) to Release Earnings on ThursdayMay 6, 2026 | americanbankingnews.comPharming Group ADR PHGMay 5, 2026 | morningstar.comMHigh Growth Tech Stocks To Watch In May 2026May 5, 2026 | finance.yahoo.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Moderate Buy" by BrokeragesMay 5, 2026 | marketbeat.comPharming Group (PHAR) Expected to Announce Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Decline in Short InterestApril 28, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Pharming Group (PHAR) and Kura Oncology (KURA)April 24, 2026 | theglobeandmail.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Decline in Short InterestApril 17, 2026 | marketbeat.comPharming Group NV - Depositary receipt (PHAR) price target increased by 43.79% to 25.84April 16, 2026 | msn.comPharming Group announces the 2026 Annual General Meeting of ShareholdersApril 16, 2026 | manilatimes.netMNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatBy Jessica Mitacek | May 2, 20263 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026PHAR, OGN, GPH, and ARTL Company DescriptionsArtelo Biosciences NASDAQ:ARTL$2.54 -0.14 (-5.22%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$2.60 +0.06 (+2.36%) As of 05/8/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Graphite One CVE:GPHC$1.17 0.00 (0.00%) As of 05/8/2026 03:59 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.Organon & Co. NYSE:OGN$13.34 +0.03 (+0.19%) Closing price 05/8/2026 03:58 PM EasternExtended Trading$13.33 -0.02 (-0.13%) As of 05/8/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Pharming Group NASDAQ:PHAR$12.98 +0.98 (+8.17%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$12.91 -0.07 (-0.54%) As of 05/8/2026 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance 3 Under-The-Radar Small Caps Making New All-Time Highs Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
